YBYanan Bie

Yanan Bie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanan Bie has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Hao Zhang

    Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China

    1 shared publication
  • Hong Chang

    Department of Traumatic Orthopedics, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China

    1 shared publication
  • Lin Zhou

    School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China; School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

    1 shared publication
  • Ming Li

    School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China

    1 shared publication
  • Qinghua Tang

    School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou Higher Education Mega Centre, Guangzhou 510006, China

    1 shared publication
  • Weichao Hao

    Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Shikonin-Loaded Nanoparticles Ameliorate DEHP-Exacerbated Psoriasis Skin Injury via Targeted Inhibition of the p38 MAPK Signaling Pathway

    by Qinghua Tang, Yixiong Li, Yan Li, Xinyuan Wang, Yanan Bie, Xuesong Yu, Lin Zhou, Ming Li

    Di-(2-ethylhexyl) phthalate (DEHP), a ubiquitous environmental plasticizer, has been increasingly linked to the exacerbation of inflammatory skin conditions, especially psoriasis. However, the mechanisms and effective therapeutic strategies targeting DEHP-aggravated psoriasis remain elusive. We integrated network toxicology, network pharmacology, and molecular docking to explore the targets of DEHP-exacerbated psoriasis and the protective effects of shikonin (SH). These findings were validated in a DEHP/IMQ-induced mouse model using a novel shikonin nanoparticle (SH-NP) that overcomes SH’s inherent hydrophobicity. Computational analyses revealed that SH counteracts DEHP skin toxicity through a multi-target network, identifying the p38 mitogen-activated protein kinase (p38 MAPK), TNF, IL-1β, proliferating cell nuclear antigen (PCNA), and matrix metalloproteinases 2 and 9 (MMP2/9) as core therapeutic nodes. Molecular docking verified this network, revealing robust binding between SH and key targets with binding energies ranging from −6.0 to −7.8 kcal/mol, consistently outperforming DEHP. In vivo experiments demonstrated that topical application of SH-NP significantly ameliorated macroscopic skin injury and reduced PASI scores. Mechanistically, SH-NP effectively reversed the DEHP-exacerbated inflammatory microenvironment by decreasing macrophage and mast cell infiltration in the dermis, reducing pro-inflammatory cytokine levels, and inhibiting the phosphorylation of p38 MAPK. Furthermore, SH-NP treatment successfully suppressed keratinocyte hyperproliferation, as evidenced by downregulated PCNA expression and reduced epidermal thickness. SH-NPs also markedly downregulated the elevated levels of MMP2/9 in mice, thereby mitigating collagen degradation and maintaining dermal matrix integrity. This study shows that SH-NPs alleviate DEHP-aggravated psoriasis by suppressing local inflammation, keratinocyte hyperproliferation, and collagen degradation, offering a targeted nanostrategy for environmentally exacerbated skin diseases.

  • H3K27ac-Activated lncRNA-DAPK1-IT1 Aggravated Oxidative Stress Damage Induced by Focal Cerebral Ischemia/Reperfusion via the miR-25-3p/HMGB1 Molecular Axis

    by Hao Zhang, Weichao Hao, Hong Chang, Yanan Bie, Xiaoou Sun

    Ischemic stroke is a prevalent neurological disorder, characterized by elevated mortality and significant long-term disability. Oxidative stress damage is an important pathological process that occurs after brain ischemia/reperfusion (I/R), in which the long non-coding RNA death-associated protein kinase 1 intronic transcript 1 (DAPK1-IT1) is aberrantly expressed and participates in oxidative stress damage; however, its specific mechanisms of action remain unclear. DAPK1-IT1 and miR-25-3p expression was detected using qRT-PCR in the mouse neuroblastoma N2a cells that received middle cerebral artery occlusion/reperfusion and oxygen-glucose deprivation/reperfusion. Functional gain and loss experiments were performed to manipulate DAPK1-IT1, miR-25-3p, and HMGB1 expression. The role of DAPK1-IT1 was assessed both in vivo and in vitro using CCK-8, flow cytometry, and western blotting. The results showed that the levels of DAPK1-IT1, HMGB1, and oxidative stress damage markers were significantly increased, whereas miR-25-3p expression was significantly downregulated. The expression levels of DAPK1-IT1 were positively correlated with ROS production. DAPK1-IT1 and HMGB1 were identified as potential targets of miR-25-3p. Knockdown of DAPK1-IT1 and HMGB1, as well as overexpression of miR-25-3p, is indeed protective and contribute to reducing oxidative stress damage by activating the Nrf2/HO-1 signaling pathway. DAPK1-IT1 overexpression caused oxidative stress damage in N2a cells by downregulating miR-25-3p expression and upregulating HMGB1 expression. Mechanistically, DAPK1-IT1 upregulated HMGB1 expression by sponging miR-25-3p and mediating histone H3 lysine 27 acetylation in the promoter region through the cAMP response element-binding protein-binding protein (CBP). In summary, we found that H3K27 acetylation-induced lncRNA-DAPK1-IT1 promotes oxidative stress damage caused by I/R through the miR-25-3p/HMGB1 axis. These findings help to improve our understanding of ischemic stroke and provide new therapeutic avenues.